This inventor holds 10 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Alnylam Pharmaceuticals, Inc., The University of Texas System. Active years: 2009-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Sulgen, CH (2010 - 2013)
- Kasendorf, DE (2009 - 2015)
- Sulgen, DE (2015)
Company Filing History:
10 out of 466 
4 out of 5,638 
Years Active: 2009-2015
Sure, here is the article about inventor Juergen Soutschek:
Title: Innovator Spotlight: Juergen Soutschek - Pioneering RNAi Therapeutics
Introduction:
Juergen Soutschek, a distinguished inventor based in Kasendorf, Germany, has made significant contributions to the field of RNA interference (RNAi) therapeutics. With a remarkable portfolio of 10 patents to his name, Juergen has been at the forefront of developing innovative methods for gene modulation and treatment of genetic disorders.
Latest Patents:
1. "RNAi modulation of ApoB and uses thereof": This patent centers around compositions and techniques for downregulating apolipoprotein B using chemically modified oligonucleotides, showcasing Juergen's expertise in RNAi technology.
2. "RNAi modulation of SCAP and therapeutic uses thereof": Introducing a novel approach to inhibiting SCAP gene expression, this patent illustrates Juergen's commitment to advancing therapeutics for diseases associated with SCAP gene expression.
Career Highlights:
Juergen Soutschek has left an indelible mark on the industry through his work with renowned organizations such as Alnylam Pharmaceuticals, Inc. and the University of Texas System. His pioneering research has led to groundbreaking advancements in the field of RNAi therapeutics, positioning him as a key figure in the realm of genetic medicine.
Collaborations:
During his career, Juergen has had the privilege of collaborating with esteemed professionals in the field, including Hans-Peter Vornlocher and Philipp Hadwiger. Their collective expertise has paved the way for innovative solutions in gene modulation and therapeutic interventions.
Conclusion:
In conclusion, Juergen Soutschek's innovative spirit and dedication to advancing RNAi therapeutics have established him as a trailblazer in the realm of genetic medicine. His groundbreaking patents and collaborations underscore his commitment to driving progress in the field, offering hope for the development of novel treatment modalities for genetic disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile